Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CORT125134 is an orally active, high‐affinity, selective antagonist of the glucocorticoid receptor that is being developed for indications that may benefit from the modulation of cortisol activity. This first‐in‐human study was conducted to evaluate the dose‐related safety, tolerability, pharmacokinetics and pharmacological effects of CORT125134 and its active metabolite CORT125201. Eighty‐one healthy male or female subjects received a single dose of 5 to 500 mg CORT125134 or matching placebo across 9 cohorts; 1 cohort received 150 mg CORT125134 after a high‐fat breakfast; and 46 subjects received 50 to 500 mg CORT125134 or matching placebo once daily for up to 14 days across 4 cohorts. CORT125134 was well tolerated at doses up to 250 mg per day for 14 days. CORT125134 was absorbed rapidly and eliminated with a mean half‐life ranging from 11 to 19 hours. Steady state was achieved by day 7. Exposure increased in a greater than proportional manner, particularly at lower doses. Exposure to CORT125201 at steady state was less than 5% that of parent CORT125134. Evidence for the desired pharmacological effect (glucocorticoid receptor antagonism) was demonstrated by the ability of CORT125134 to prevent several effects of the glucocorticoid receptor agonist prednisone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease
Oakley, R. H., & Cidlowski, J. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.007 · Cited by 1,068
Cole, T. J., Blendy, J. A., Monaghan, A. P., Krieglstein, K., Schmid, W., Aguzzi, A., Fantuzzi, G., Hummler, E., Unsicker, K., & Schütz, G. (1995) · Genes & Development · doi:10.1101/gad.9.13.1608 · Cited by 946
Glucocorticoid receptor signaling in health and disease
Kadmiel, M., & Cidlowski, J. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.07.003 · Cited by 849
Vermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C., & Jansen, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020354 · Cited by 285
Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor
Clark, A. R., & Belvisi, M. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.004 · Cited by 209
Ewald, E. R., Wand, G. S., Seifuddin, F., Yang, X., Tamashiro, K. L., Potash, J. B., Zandi, P., & Lee, R. S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.003 · Cited by 105
Cited by
Crucian, B. E., Choukèr, A., Simpson, R. J., Mehta, S., Marshall, G., Smith, S. M., Zwart, S. R., Heer, M., Ponomarev, S., Whitmire, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01437 · Cited by 421
Long-term effects of glucocorticoid excess on the brain
Dekkers, A. J., Amaya, J. M., van der Meulen, M., Biermasz, N. R., Meijer, O. C., & Pereira, A. M. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13142 · Cited by 56
Glucocorticoid receptor modulators decrease alcohol self-administration in male rats
McGinn, M. A., Tunstall, B. J., Schlosburg, J. E., Gregory-Flores, A., George, O., de Guglielmo, G., Mason, B. J., Hunt, H. J., Koob, G. F., & Vendruscolo, L. F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108510 · Cited by 35
Self-citationWhat is the role of medical therapy in adrenal-dependent Cushing’s syndrome?
Braun, L. T., & Reincke, M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101376 · Cited by 21
Metadata
- Authors
- Hunt, H., Donaldson, K., Strem, M., Zann, V., Leung, P., Sweet, S., Connor, A., Combs, D., & Belanoff, J.
- Venue
- Clinical Pharmacology in Drug Development
- Publisher
- Wiley
- Published
- 2017-10-02
- Volume
- 7
- Issue
- 4
- Pages
- 408-421
- ISSN
- 2160-763X (ISSN-L)
- 2160-7648
- OpenAlex
- W2762121884
- Cited by
- 65
- References
- 6
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study. https://app.cochat.ai/papers/10.1002/cpdd.389
- The paper
- Hunt, H., Donaldson, K., Strem, M., Zann, V., Leung, P., Sweet, S., Connor, A., Combs, D., & Belanoff, J. (2018). Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.